What's in Bausch Health Americas, Inc.'s pipeline?

Bausch Health Americas, Inc. has 59 drugs in our index: 15 marketed, 0 filed, 25 in Phase 3, 14 in Phase 2, 3 in Phase 1.

Which companies overlap with Bausch Health Americas, Inc.'s portfolio?

Top competitors by shared drug class: LEO Pharma, Pfizer, Assistance Publique - Hôpitaux de Paris, Galderma R&D, Federal University of São Paulo.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bausch-health-americas-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Bausch Health Americas, Inc. — Portfolio Competitive Intelligence Brief

Bausch Health Americas, Inc. pipeline: 15 marketed, 0 filed, 25 Phase 3, 14 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

15 marketed 0 filed 25 Phase 3 14 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
High dose budesonide rectal foam	High dose budesonide rectal foam	marketed	Corticosteroid	Glucocorticoid receptor	Gastroenterology / Immunology
Low dose budesonide rectal foam	Low dose budesonide rectal foam	marketed	Corticosteroid	Glucocorticoid receptor	Gastroenterology
benzoyl peroxide wash	benzoyl peroxide wash	marketed
Adapalene Gel	Adapalene Gel	marketed	Retinoid	Retinoic acid receptor gamma (RAR-γ)	Dermatology
Tazorac Cream	Tazorac Cream	marketed
Adapalene/Benzoyl Peroxide Facial Gel	Adapalene/Benzoyl Peroxide Facial Gel	marketed	Retinoid and peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)	Dermatology
Poly-L-Lactic Acid	Poly-L-Lactic Acid	marketed
Tretinoin Facial Gel	Tretinoin Facial Gel	marketed
IDP-122 Lotion	IDP-122 Lotion	marketed
Methylnaltrexone (MNTX)	Methylnaltrexone (MNTX)	marketed	Peripheral mu-opioid receptor antagonist	Mu-opioid receptor (peripheral)	Gastroenterology / Pain Management
Luliconazole Cream 1%	Luliconazole Cream 1%	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)	Dermatology
Tretinoin gel	Tretinoin gel	marketed	Retinoid	Retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma)	Dermatology

Therapeutic area mix

Dermatology · 19
Gastroenterology · 5
Neuroscience · 2
Other · 2
Gastroenterology / Supportive Care · 2
Gastroenterology / Immunology · 2
Virology/Dermatology · 1
Gastroenterology / Pain Management · 1
Gastrointestinal · 1
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

LEO Pharma · 4 shared drug classes
Pfizer · 3 shared drug classes
Assistance Publique - Hôpitaux de Paris · 3 shared drug classes
Galderma R&D · 3 shared drug classes
Federal University of São Paulo · 3 shared drug classes
Wyeth is now a wholly owned subsidiary of Pfizer · 3 shared drug classes
Ache Laboratorios Farmaceuticos S.A. · 2 shared drug classes
Astellas Pharma Inc · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Bausch Health Americas, Inc.:

Cite this brief

Drug Landscape (2026). Bausch Health Americas, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bausch-health-americas-inc. Accessed 2026-05-16.